Recent News

• 03.03.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.19.2025 - Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
• 02.12.2025 - Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
• 02.03.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.13.2025 - Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
• 01.02.2025 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 02.24.2025 - 8-K Current report
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.19.2025 - 8-K Current report
• 02.19.2025 - EX-99.1 EX-99.1
• 02.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - 8-K Current report
• 01.30.2025 - 8-K Current report